Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

37.55USD
7 Dec 2016
Change (% chg)

$-0.14 (-0.37%)
Prev Close
$37.69
Open
$37.47
Day's High
$37.62
Day's Low
$37.20
Volume
993,848
Avg. Vol
665,969
52-wk High
$45.58
52-wk Low
$37.20

GSK.N

Chart for GSK.N

About

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $90,237.59
Shares Outstanding(Mil.): 2,438.11
Dividend: 0.46
Yield (%): 5.54

Financials

  GSK.N Industry Sector
P/E (TTM): 247.96 30.14 30.77
EPS (TTM): 0.15 -- --
ROI: 0.87 15.85 15.23
ROE: 10.81 16.96 16.56

Exclusive: Novartis in talks to sell some central nervous system drugs - sources

ZURICH Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth.

Dec 06 2016

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

LONDON GlaxoSmithKline said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse.

Dec 05 2016

BRIEF-GlaxoSmithKline submits marketing application for shingles vaccine to EMA

* GSK announces EU regulatory submission of candidate vaccine for prevention of shingles

Nov 25 2016

GSK chases Astra with start of big anemia drug trials

LONDON GlaxoSmithKline has started pivotal trials of an experimental anemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

Nov 24 2016

GSK chases Astra with start of big anaemia drug trials

LONDON, Nov 24 GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

Nov 24 2016

BRIEF-GSK's Mepolizumab meets endpoints in phase 3 EGPA study

* Phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis

Nov 23 2016

BRIEF-GSK receives FDA approval for expanded indication for flulaval quadrivalent (influenza vaccine) for infants 6 months and older

* GSK receives FDA approval for expanded indication for flulaval quadrivalent (influenza vaccine) for infants 6 months and older Source text for Eikon: Further company coverage:

Nov 21 2016

BRIEF-GSK files regulatory submission of candidate vaccine

* GSK files regulatory submission of candidate vaccine for prevention of shingles in Canada

Nov 21 2016

GlaxoSmithKline seeks U.S. approval for triple lung drug

LONDON GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light.

Nov 21 2016

GlaxoSmithKline seeks U.S. approval for triple lung drug

LONDON, Nov 21 GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light.

Nov 21 2016

Earnings vs. Estimates